Th17 Cells in Alemtuzumab-Treated Patients: The Effect of Long-Term Maintenance Immunosuppressive Therapy | Zendy

Joanna Hester | Zendy; Natalie Mills | Zendy; Sushma Shankar | Zendy; Manuela CarvalhoGaspar | Zendy; Peter J. Friend | Zendy; Kathryn J. Wood | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Th17 Cells in Alemtuzumab-Treated Patients: The Effect of Long-Term Maintenance Immunosuppressive Therapy

Author(s) -

Joanna Hester,

Natalie Mills,

Sushma Shankar,

Manuela CarvalhoGaspar,

Peter J. Friend,

Kathryn J. Wood

Publication year - 2011

Publication title -

transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.45

H-Index - 204

eISSN - 1534-6080

pISSN - 0041-1337

DOI - 10.1097/tp.0b013e31820c85dc

Subject(s) - alemtuzumab , medicine , term (time) , maintenance therapy , immunology , intensive care medicine , chemotherapy , antibody , physics , quantum mechanics

Leukocyte depletion at the time of transplantation with alemtuzumab (Campath-1H) has been demonstrated to be a potential strategy for reducing long-term exposure to immunosuppressive drugs. Although the impact of alemtuzumab treatment on the immune system has been explored, the effects of long-term immunosuppressive therapy in alemtuzumab-treated patients still need to be elucidated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research